Is the Fractyl Health (GUTS) investment thesis intact?

It is under pressure. Readouts currently rates the Fractyl Health Thesis Challenged. Revita met its six-month pivotal goal; De Novo submission planned for late Q4 2026.

What is the next catalyst for Fractyl Health (GUTS)?

The next dated event is DE NOVO submission for Revita, expected late Q4 2026, as stated by the company. Also ahead: Pivotal topline results (REMAIN-1) for Revita, expected Q1 2027.

How long will Fractyl Health's cash last?

Fractyl Health has said its cash will fund operations into Q2 2027 (guidance as of October 22, 2026).

GUTSFractyl Health, Inc.

ChallengedLast material event Oct 22, 2026 · Updated Oct 30, 2026

Revita met its six-month pivotal goal; De Novo submission planned for late Q4 2026

Fractyl Health develops Revita, an endoscopic procedure on the duodenum to help people keep weight off after stopping GLP-1 drugs; it is not approved.

Revita's randomized REMAIN-1 pivotal cohort met its six-month co-primary endpoint after GLP-1 discontinuation, with weight regain of 5.1% versus 8.2% for sham. Its second co-primary endpoint is expected in Q1 2027; a De Novo submission is planned for late Q4 2026. Fractyl discontinued internal Rejuva development and plans approximately 45% workforce reductions. Management expects cash into Q2 2027, before potential authorization in late 2027. Funding and Nasdaq listing risks remain central; patient interest supports commercial planning but leaves reimbursement uncertain.

Thesis checklist

1 risk needs attention

Select a row for evidence

What must be trueStateNext proof

12-month endpoint is metAwaiting evidenceREMAIN-1 pivotal 12-month topline results, including the second co-primary endpoint.Next: REMAIN-1 pivotal 12-month topline results, including the second co-primary endpoint.

Why it is in this state

The evidence, what would weaken it and the source filing

De Novo is filedAwaiting evidenceCompany confirmation that the De Novo marketing application has been submitted with the complete safety dataset.Next: Company confirmation that the De Novo marketing application has been submitted with the complete safety dataset.

Why it is in this state

The evidence, what would weaken it and the source filing

Funding reaches approvalAt riskFinancing sufficient to reach potential authorization, execution of expense reductions, and the Nasdaq hearing outcome.Next: Financing sufficient to reach potential authorization, execution of expense reductions, and the Nasdaq hearing outcome.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

REMAIN-1 pivotal durability result

Tests: 12-month endpoint is met

Q1 2027 (company guidance)

Does Revita meet the pivotal second co-primary endpoint for sustained weight loss?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

ChallengedCurrentCorporate

-4.4%Oct 22, 2026

Revita met its six-month pivotal goal; De Novo submission planned for late Q4 2026

ChallengedClinical

+4.0%Aug 10, 2026

Revita's GLP-1 weight-regain data are compelling, but a going-concern clock expires before pivotal results can support a De Novo filing

IntactClinical

-7.5%Jun 4, 2026

Revita's pivotal REMAIN-1 readout will determine whether an endoscopic duodenal procedure can durably prevent weight regain after GLP-1 discontinuation

IntactClinical

-68.0%Jan 29, 2026

REMAIN-1 Midpoint 6-month weight maintenance data positive

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Obesity· post-GLP-1 discontinuation

Revita · 5 upcoming · 6 completed

DE NOVO Submission

late Q4 2026

Category III CPT code 1122T procedure takes effect

January 1, 2027

Data: ToplineREMAIN-1Pivotal

Q1 2027

Regulatory Decision

Late 2027

Commercial Launch

Early 2028

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Fractyl Health (GUTS) investment thesis intact?: It is under pressure. Readouts currently rates the Fractyl Health Thesis Challenged. Revita met its six-month pivotal goal; De Novo submission planned for late Q4 2026.
What is the next catalyst for Fractyl Health (GUTS)?: The next dated event is DE NOVO submission for Revita, expected late Q4 2026, as stated by the company. Also ahead: Pivotal topline results (REMAIN-1) for Revita, expected Q1 2027.
How long will Fractyl Health's cash last?: Fractyl Health has said its cash will fund operations into Q2 2027 (guidance as of October 22, 2026).

Other companies we cover in these diseases

Obesity: Arrowhead Pharmaceuticals (ARWR)Ascendis Pharma (ASND)Biohaven (BHVN)BioAge Labs (BIOA)iBio (IBIO)Palatin Technologies (PTN)Silence Therapeutics (SLN)Viking Therapeutics (VKTX)Structure Therapeutics (GPCR)

Disease areas: Obesity, diabetes and heart disease
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

11 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.